RxDoctor Payments Data

Bharat Upadhyay, MD

Pulmonary Disease · Port St Lucie, FLNPI 1912951740

Payments from drug & device makers

$299,302in general payments, 2019–2025

Across 353 payments — averaging $847.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$297K
  • Actelion Pharmaceuticals US, Inc.$480
  • Fisher & Paykel Healthcare Inc$194
  • GSK$193
  • Verona Pharma, Inc.$174
  • Insmed, Inc.$143
  • plus $977 from 23 others

What the payments were for

  • Consulting fees$2,7901%
  • Speaking & faculty fees$251,03984%
  • Travel & lodging$36,22612%
  • Food & beverage$9,0403%
  • Education$1640%
  • Other$440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$299,302 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$242,562
Medicare patients
703
Services billed
3,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol549$512,890
Trelegy ElliptaFluticasone/Umeclidin/Vilanter427$402,991
Stiolto RespimatTiotropium Br/Olodaterol Hcl234$179,271
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr226$155,028
OpsumitMacitentan12$151,688
Breo ElliptaFluticasone/Vilanterol132$79,221
Bevespi AerosphereGlycopyrrolate/Formoterol Fum82$47,771
Arnuity ElliptaFluticasone Furoate105$31,010
Albuterol Sulfate HfaAlbuterol Sulfate1,089$30,551
Spiriva RespimatTiotropium Bromide32$29,494
Spiriva HandihalerTiotropium Bromide21$25,236
SymbicortBudesonide/Formoterol Fumarate50$22,851
EliquisApixaban27$18,548
Wixela InhubFluticasone Propion/Salmeterol60$14,696
Fluticasone-SalmeterolFluticasone Propion/Salmeterol73$13,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$193$676,768910 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$297,142$583,512681 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$49$208,765266 claims
Actelion Pharmaceuticals US, Inc.Opsumit$480$151,68812 claims
PfizerEliquis$30$18,54827 claims
Johnson & JohnsonXarelto$21$12,68611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →